TY - JOUR
T1 - Inhalation phage therapy as a new approach to preventing secondary bacterial pneumonia in patients with moderate to severe COVID-19
T2 - A double-blind clinical trial study
AU - Samaee, Hamid Reza
AU - Eslami, Gohar
AU - Rahimzadeh, Golnar
AU - Saeedi, Majid
AU - Davoudi Badabi, Alireza
AU - Asare-Addo, Kofi
AU - Nokhodchi, Ali
AU - Roozbeh, Fatemeh
AU - Moosazadeh, Mahmood
AU - Ghasemian, Roya
AU - Alikhani, Ahmad
AU - Rezai, Mohammad Sadegh
N1 - Funding Information:
The authors would like to thank the Pediatric Infectious Diseases Research Center lab at Bou-Ali Sina Hospital in Sari for performing laboratory tests and for their cooperation in the use of equipment and materials in their laboratory.
Publisher Copyright:
© 2023 The Authors
PY - 2023/6/1
Y1 - 2023/6/1
N2 - Inhalation phage therapy is proposed as a replacement approach for antibiotics in the treatment of pulmonary bacterial infections. This study investigates phage therapy on bacterial pneumonia in patients with moderate to severe COVID-19 via the inhalation route. In this double-blind clinical trial, 60 patients with positive COVID-19 hospitalized in three central Mazandaran hospitals were chosen and randomly divided into two intervention and control groups. Standard country protocol drugs plus 10 mL of phage suspension every 12 h with a mesh nebulizer was prescribed for 7 days in the intervention group. The two groups were compared in terms of O2Sat, survival rate, severe secondary pulmonary bacterial infection and duration of hospitalization. Comparing the results between the intervention and control group, in terms of the trend of O2Sat change, negative sputum culture, no fever, no dyspnea, duration of hospitalization, duration of intubation and under ventilation, showed that the difference between these two groups was statistically different (P value < 0.05). In conclusion, inhalation phage therapy may have a potential effect on secondary infection and in the outcome of COVID-19 patients. However, more clinical trials with control confounding factors are needed to further support this concept.
AB - Inhalation phage therapy is proposed as a replacement approach for antibiotics in the treatment of pulmonary bacterial infections. This study investigates phage therapy on bacterial pneumonia in patients with moderate to severe COVID-19 via the inhalation route. In this double-blind clinical trial, 60 patients with positive COVID-19 hospitalized in three central Mazandaran hospitals were chosen and randomly divided into two intervention and control groups. Standard country protocol drugs plus 10 mL of phage suspension every 12 h with a mesh nebulizer was prescribed for 7 days in the intervention group. The two groups were compared in terms of O2Sat, survival rate, severe secondary pulmonary bacterial infection and duration of hospitalization. Comparing the results between the intervention and control group, in terms of the trend of O2Sat change, negative sputum culture, no fever, no dyspnea, duration of hospitalization, duration of intubation and under ventilation, showed that the difference between these two groups was statistically different (P value < 0.05). In conclusion, inhalation phage therapy may have a potential effect on secondary infection and in the outcome of COVID-19 patients. However, more clinical trials with control confounding factors are needed to further support this concept.
KW - COVID-19
KW - Nebulizer
KW - Phage therapy
KW - Secondary infection
UR - http://www.scopus.com/inward/record.url?scp=85153799428&partnerID=8YFLogxK
U2 - 10.1016/j.jddst.2023.104486
DO - 10.1016/j.jddst.2023.104486
M3 - Article
AN - SCOPUS:85153799428
VL - 84
JO - Journal of Drug Delivery Science and Technology
JF - Journal of Drug Delivery Science and Technology
SN - 1773-2247
M1 - 104486
ER -